Dyne Therapeutics (NASDAQ:DYN) PT Raised to $42.00

Dyne Therapeutics (NASDAQ:DYN) had its price target boosted by Jefferies Financial Group from $36.00 to $42.00 in a research note released on Monday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

DYN has been the topic of several other research reports. Morgan Stanley assumed coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They issued an overweight rating and a $40.00 price target on the stock. Stifel Nicolaus boosted their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a buy rating in a research note on Wednesday, March 6th. HC Wainwright upped their price target on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the stock a buy rating in a research note on Monday. Chardan Capital reiterated a buy rating and issued a $31.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. Finally, Piper Sandler upped their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an overweight rating in a report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of Moderate Buy and a consensus price target of $40.78.

Dyne Therapeutics Trading Down 3.4 %

Shares of Dyne Therapeutics stock opened at $31.53 on Monday. Dyne Therapeutics has a twelve month low of $6.40 and a twelve month high of $35.98. The stock has a market capitalization of $2.76 billion, a P/E ratio of -7.94 and a beta of 1.00. The business’s fifty day moving average price is $26.96 and its 200 day moving average price is $20.43.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting the consensus estimate of ($0.81). As a group, sell-side analysts predict that Dyne Therapeutics will post -3.1 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Wildon Farwell sold 1,585 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the transaction, the insider now owns 151,590 shares of the company’s stock, valued at $3,895,863. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Oxana Beskrovnaya sold 30,426 shares of the stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $32.96, for a total value of $1,002,840.96. Following the completion of the transaction, the insider now owns 149,647 shares of the company’s stock, valued at $4,932,365.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Wildon Farwell sold 1,585 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the transaction, the insider now directly owns 151,590 shares of the company’s stock, valued at approximately $3,895,863. The disclosure for this sale can be found here. Insiders sold 1,094,383 shares of company stock worth $26,724,672 over the last ninety days. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DYN. Wetzel Investment Advisors Inc. acquired a new position in Dyne Therapeutics in the first quarter worth about $28,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Dyne Therapeutics by 58.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after purchasing an additional 3,092 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Dyne Therapeutics by 95.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock worth $83,000 after buying an additional 4,552 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Dyne Therapeutics by 355.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after buying an additional 5,541 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Dyne Therapeutics by 10.7% during the third quarter. Principal Financial Group Inc. now owns 15,229 shares of the company’s stock worth $136,000 after buying an additional 1,476 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.